Loading
Senior author of the UK's two standard-setting biliary trials, ABC-02 and BILCAP, chief investigator of ABC-06, and UK lead of the first-line precision medicine trial SAFIR-ABC10.
John Bridgewater is professor of medical oncology at the UCL Cancer Institute and a consultant at UCLH. He was senior author on ABC-02 (gemcitabine plus cisplatin as first-line standard) and BILCAP (adjuvant capecitabine), chief investigator of ABC-06 (second-line FOLFOX) and leads the National Cancer Research Institute biliary tract subgroup. He leads the UK arm of SAFIR-ABC10, sponsored by UCL and UCLH, which profiles tumours and matches patients with cholangiocarcinoma or gallbladder cancer to one of seven targeted therapies, and co-authored the 2023 British Society of Gastroenterology cholangiocarcinoma guideline.
Shares ABC-06, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tags biliary, trialist.
Shares AMMF, the Cholangiocarcinoma Charity, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tags biliary, uk.
Shares ABC-02, ABC-06, Biliary tract cancer (cholangiocarcinoma) and the tags biliary, trialist.
Shares BILCAP, Biliary tract cancer (all types) and the tags biliary, trialist.
Shares Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tags biliary, uk.
Shares Biliary tract cancer (all types), Capecitabine, Gemcitabine and the tags trialist, uk.
Shares AMMF, the Cholangiocarcinoma Charity, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag uk.
Shares AMMF, the Cholangiocarcinoma Charity, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag uk.